Oxford BioDynamics to identify NSCLC biomarkers for two global pharmas
Oxford BioDynamics plc (LSE:OBD) said it partnered with two "top 10" global pharmas to use its EpiSwitch epigenetic biomarker platform to identify non-small cell lung cancer (NSCLC) biomarkers from patients which may help differentiate responders from non-responders to an anti-PD-L1 therapy. The pharmas have an existing collaboration involving the therapy. ...
BCIQ Company Profiles
BCIQ Target Profiles